<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962973</url>
  </required_header>
  <id_info>
    <org_study_id>CAR2016-01</org_study_id>
    <secondary_id>CIV-FR-16-09-016865</secondary_id>
    <nct_id>NCT02962973</nct_id>
  </id_info>
  <brief_title>European Clinical Evaluation of the Carmat Total Artificial Heart</brief_title>
  <acronym>ADVANCE HF</acronym>
  <official_title>Clinical Evaluation of the Carmat Total Artificial Heart for Patients With Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmat SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmat SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to evaluate the safety and performance of the
      Carmat Total Artificial Heart (TAH) in patients suffering from advanced heart failure and
      requiring biventricular support.

      Each subject receiving the Carmat TAH is followed to the primary and secondary endpoints at 6
      months, with a subsequent follow-up period extending to 2 years post implant.

      The results of the study will be used to support a CE mark application.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>180 days</time_frame>
    <description>The primary objective of the study is survival on a Carmat device at 180 days post-implant or survival to cardiac transplantation if occurring before 180 days post-implant.
The primary endpoint will be presented as a proportion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the NHYA classicafication</measure>
    <time_frame>180 days</time_frame>
    <description>NYHA classification will be assessed at baseline and 1, 3, 6 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the 6 Minutes Walk Test</measure>
    <time_frame>180 days</time_frame>
    <description>The 6MWT will be assessed at baseline and 1, 3, 6 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the Quality Of Life assessed with EQ-ED-5L questionnaire</measure>
    <time_frame>180 days</time_frame>
    <description>The EQ-5D-5L health index and Visual Analogue Scale (VAS) scores will be assessed at baseline and 1, 3, 6 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the Quality Of Life assessed with SF36 questionnaire</measure>
    <time_frame>180 days</time_frame>
    <description>The SF36 Mental Component Summary and Physical Component Summary scores will be assessed at baseline and 1, 3, 6 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>180 days</time_frame>
    <description>Adverse events per INTERMACS definitions, collected during the study course
Frequency and incidence of all adverse events
Frequency and incidence of pre-defined anticipated adverse events
Frequency, incidence and type of device malfunction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Advanced Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patient implanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CARMAT Total Artificial Heart</intervention_name>
    <arm_group_label>Patient implanted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
    <arm_group_label>Patient implanted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age: 18 to 75 years

          2. Inotrope dependent or cardiac Index (CI) &lt; 2.2 L/min/m2 while not on inotropes

          3. On Optimal Medical Management as judged by the investigator based on current Heart
             Failure practice guidelines (ESC/AHA)

          4. Eligible to biventricular Mechanical Circulatory Support according to ISHLT guidelines
             for mechanical circulatory support:

               1. Biventricular failure with at least two of the following hemodynamic/
                  echocardiographic measurements implying right heart failure:

                    -  RVEF ≤ 30%

                    -  RVSWI ≤ 0.25 mmHg*L/m2

                    -  TAPSE ≤ 14mm

                    -  RV-to-LV end-diastolic diameter ratio &gt; 0.72

                    -  CVP &gt; 15mmHg

                    -  CVP-to-PCWP ratio &gt; 0.63

                    -  Tricuspid insufficiency grade 4

               2. Treatment-refractory recurrent and sustained ventricular tachycardia or
                  ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic
                  substrate

               3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic
                  cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease)

          5. Not eligible for transplant or eligible and age 55 year or older with an expected
             waiting time for heart transplant exceeding 12 months as estimated by physician.

          6. Anatomic compatibility confirmed using 3D imaging (CT-scan)

          7. Patient's affiliation to health care insurance

          8. Signed informed consent obtained

        Exclusion Criteria:

          1. Body Mass Index (BMI) &lt; 15 or &gt; 47

          2. Existence of any ongoing non-temporary mechanical circulatory support

          3. Existence of any temporary mechanical circulatory support other than IABP

          4. History of cardiac or other organ transplant

          5. Patients who have required cardiopulmonary resuscitation for &gt; 30 minutes within 14
             days prior to implant

          6. Known intolerance to anticoagulant or antiplatelet therapies

          7. Coagulopathy defined by platelets &lt; 100k/µl or INR ≥ 1.5 not due to anticoagulant
             therapy

          8. Cerebro-vascular accident &lt; 3 months or symptomatic or a known &gt; 80% carotid stenosis

          9. Known abdominal or thoracic aortic aneurysm &gt; 5 cm

         10. End-organ dysfunction as per investigator judgment and following but not limited
             criteria:

               1. Total bilirubin &gt; 100 µmol/L (5,8 mg/dl) or cirrhosis evidenced by ultrasound,
                  CT-scan or positive biopsy

               2. GFR &lt; 30ml/min/1.73m2

         11. History of severe Chronic Obstructive Pulmonary Disease or severe restrictive lung
             disease

         12. Recent blood stream infection (&lt;= 7 days)

         13. Documented amyloid light-chain (AL amyloidosis)

         14. Hemodynamically significant peripheral vascular disease accompanied by rest pain or
             extremity ulceration

         15. Illness, other than heart disease, that would limit survival to less than 1 year

         16. Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely
             to impair compliance with the study protocol and TAH management

         17. Participation in any other clinical investigation that is likely to confound study
             results or affect the study

         18. Pregnancy or breast feeding (woman in age of childbearing will have to show negative
             pregnancy test)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Jansen, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Carmat SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Vacher</last_name>
    <phone>+33(0)6 34 92 86 84</phone>
    <email>clinique@carmatsas.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Vacher</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital cardiologique</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud De Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Laënnec</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospice Civil de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Du Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced heart failure</keyword>
  <keyword>Total artificial heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

